Oilers 88 Energy Limited and Eland Oil & Gas gush higher after updates
A look at some of the highlight movers, up and down, on Friday in London
Company
Shield Therapeutics PLC
LON:STX
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer ® /Feraccru ® (ferric maltol). The group has launched Accrufer® in the US and Feraccru ® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical for the development and commercialization of Accrufer ® / Feraccru ® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co in the Republic of Korea, and with KYE Pharmaceuticals in Canada.
175 stories · page 9 of 9
Investments and investor services
FTSE 100 closes firmly lower on chilly Wednesday with ITV the big switch-off
The Footsie may have mainly traded sideways throughout the day but there have been some notable movements among blue-chips.
Archive
Advertising key to ITV's latest results broadcast; Taylor Wimpey continues housebuilder updates
Day ahead includes full-year results from blue chips including broadcaster ITV PLC, housebuilder Taylor Wimpey PLC, motor insurer Admiral PLC, and mid cap estate agents Foxton's PLC
Shield Therapeutics slumps as flagship drug fails pivotal Phase III trial
Feraccru is already available to treat iron deficiency anaemia (IDA) in patients with irritable bowel disease, but Shield was trying to show that it is effective at treating IDA in people with chronic kidney disease as well
Kosmos Energy falls as tests at Requin Tigre-1 exploration well in Senegal fail to detect any hydrocarbons
A look at some of the London market's biggest risers and fallers on Monday
Archive
Kingisher can't afford another duff trading update
Trading can change as fast as the weather for a home improvements retailer; not many are expecting it to have changed for the better for Kingfisher
Shield Therapeutics to raise £12mln to fund further development and commercialisation of Feraccru
“These funds will enable us to reach and go beyond the upcoming key inflection points”
Archive
ASOS expected to post another set of strong results
Analysts aren’t forecasting any surprises when the popular online fashion retailer reports its interims on Tuesday
Archive
ASOS tipped to show strength
Week ahead: Asos, Panmure Gordon, Sprue Aegis, Electrocomponents
Feraccru approval caps ‘transformational’ year for Shield
The pharmaceutical firm achieved marketing authorisation for its iron deficiency anaemia treatment Feraccru in February